Original Article

You have free access to this content

Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy

  1. Samuel Bral MD1,†,*,
  2. Michaël Duchateau MSc1,
  3. Harijati Versmessen MD1,
  4. Douwe Verdries MD2,
  5. Benedikt Engels MD1,
  6. Mark De Ridder MD, PhD1,
  7. Koen Tournel MSc1,
  8. Christine Collen MD1,
  9. Hendrik Everaert MD, PhD3,
  10. Denis Schallier MD, PhD4,
  11. Jacques De Greve MD, PhD4,
  12. Guy Storme MD, PhD1

Article first published online: 13 NOV 2009

DOI: 10.1002/cncr.24732

Issue

Cancer

Cancer

Volume 116, Issue 1, pages 241–250, 1 January 2010

Additional Information

How to Cite

Bral, S., Duchateau, M., Versmessen, H., Verdries, D., Engels, B., Ridder, M. D., Tournel, K., Collen, C., Everaert, H., Schallier, D., De Greve, J. and Storme, G. (2010), Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy. Cancer, 116: 241–250. doi: 10.1002/cncr.24732

Author Information

  1. 1

    Department of Radiation Oncology, Oncology Center, Brussels University Hospital, Brussels, Belgium

  2. 2

    Department of Radiology, Oncology Center, Brussels University Hospital, Brussels, Belgium

  3. 3

    Department of Nuclear Medicine, Oncology Center, Brussels University Hospital, Brussels, Belgium

  4. 4

    Department of Medical Oncology, Oncology Center, Brussels University Hospital, Brussels, Belgium

  1. †

    Fax: (011) 32 2 477 5450

*Department of Radiation Oncology, Oncologisch Centrum, Universitair Ziekenhuis, Laarbeeklaan 101, Brussels 1090 Belgium

Publication History

  1. Issue published online: 11 JAN 2010
  2. Article first published online: 13 NOV 2009
  3. Manuscript Accepted: 4 MAY 2009
  4. Manuscript Revised: 20 APR 2009
  5. Manuscript Received: 30 JAN 2009

Funded by

  • “Fonds voor Wetenschappelijk Onderzoek-Vlaanderen (FWO),”. Grant Numbers: G.0486.06, G.0412.08
  • “Wetenschappelijk fonds Willy Gepts”
  • Sanofi-Aventis

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS